U.S. investors and large pharmaceutical companies are increasingly doing deals in China as the country’s biopharma sector ...

Access to data and to skills specific to AI are among the key challenges pharma companies face to unlock the technology’s ...

Shares of healthcare products company West Pharmaceutical Services (NYSE:WST) fell 34.9% in the afternoon session after the ...

Vishal Manchanda highlights the potential challenges the pharmaceutical sector may face in FY27 due to reliance on key drugs ...

Should you invest $1,000 in Hims & Hers Health right now? Before you buy stock in Hims & Hers Health, consider this: The Motley Fool Stock Advisor analyst team just identified wha ...

The grants have been the source of new treatments for cancer, heart disease, diabetes, strokes and H.I.V.; wonder drugs like ...

Using money from the opioid settlement funds from big pharmaceutical companies, St. Johns County will partner with EPIC ...

Many investors seemed to view Nvidia's decision to maintain its stake in Recursion as a vote of confidence in the company.

Vaccine policy, Medicare drug negotiations, and a potential DTC advertising ban will all fall under Kennedy’s purview as HHS ...

Biogen’s disappointing Leqembi performance and weak pipeline hurt future growth. Learn why BIIB stock is rated "sell" due to ...

The president has said the law is unfair to U.S. businesses. But lawyers say weakening it could end up costing corporate ...

Swedish biotech company Gesynta Pharma AB has secured $27 million in a Series B financing round led by Innovestor Life Science in Finland.